...
首页> 外文期刊>BMC Medical Genomics >Virtual CGH: an integrative approach to predict genetic abnormalities from gene expression microarray data applied in lymphoma
【24h】

Virtual CGH: an integrative approach to predict genetic abnormalities from gene expression microarray data applied in lymphoma

机译:虚拟CGH:从淋巴瘤中应用的基因表达微阵列数据预测遗传异常的综合方法

获取原文
           

摘要

Background Comparative Genomic Hybridization (CGH) is a molecular approach for detecting DNA Copy Number Alterations (CNAs) in tumor, which are among the key causes of tumorigenesis. However in the post-genomic era, most studies in cancer biology have been focusing on Gene Expression Profiling (GEP) but not CGH, and as a result, an enormous amount of GEP data had been accumulated in public databases for a wide variety of tumor types. We exploited this resource of GEP data to define possible recurrent CNAs in tumor. In addition, the CNAs identified by GEP would be more functionally relevant CNAs in the disease pathogenesis since the functional effects of CNAs can be reflected by altered gene expression. Methods We proposed a novel computational approach, coined virtual CGH (vCGH), which employs hidden Markov models (HMMs) to predict DNA CNAs from their corresponding GEP data. vCGH was first trained on the paired GEP and CGH data generated from a sufficient number of tumor samples, and then applied to the GEP data of a new tumor sample to predict its CNAs. Results Using cross-validation on 190 Diffuse Large B-Cell Lymphomas (DLBCL), vCGH achieved 80% sensitivity, 90% specificity and 90% accuracy for CNA prediction. The majority of the recurrent regions defined by vCGH are concordant with the experimental CGH, including gains of 1q, 2p16-p14, 3q27-q29, 6p25-p21, 7, 11q, 12 and 18q21, and losses of 6q, 8p23-p21, 9p24-p21 and 17p13 in DLBCL. In addition, vCGH predicted some recurrent functional abnormalities which were not observed in CGH, including gains of 1p, 2q and 6q and losses of 1q, 6p and 8q. Among those novel loci, 1q, 6q and 8q were significantly associated with the clinical outcomes in the DLBCL patients (p Conclusions We developed a novel computational approach, vCGH, to predict genome-wide genetic abnormalities from GEP data in lymphomas. vCGH can be generally applied to other types of tumors and may significantly enhance the detection of functionally important genetic abnormalities in cancer research.
机译:背景技术比较基因组杂交(CGH)是一种检测肿瘤中DNA拷贝数变化(CNA)的分子方法,这是肿瘤发生的关键原因之一。然而,在后基因组时代,大多数癌症生物学研究都集中在基因表达谱分析(GEP)而非CGH上,结果,在公共数据库中已收集了大量关于各种肿瘤的GEP数据类型。我们利用GEP数据的这种资源来定义可能在肿瘤中复发的CNA。另外,通过GEP鉴定的CNA在疾病发病机理中将在功能上与CNA在功能上更相关,因为CNA的功能作用可以通过改变的基因表达来反映。方法我们提出了一种新颖的计算方法,称为虚拟CGH(vCGH),该方法采用隐马尔可夫模型(HMM)从其相应的GEP数据预测DNA CNA。首先对vCGH进行训练,该配对是从足够数量的肿瘤样本生成的GEP和CGH配对数据中进行的,然后将其应用于新肿瘤样本的GEP数据以预测其CNA。结果通过对190例弥漫性大B细胞淋巴瘤(DLBCL)进行交叉验证,vCGH的CNA预测灵敏度达到80%,特异性为90%,准确性为90%。 vCGH定义的大部分重复区域与实验CGH一致,包括1q,2p16-p14、3q27-q29、6p25-p21、7、11q,12和18q21的增益,以及6q,8p23-p21的损耗, DLBCL中的9p24-p21和17p13。此外,vCGH预测了一些在CGH中未发现的复发性功能异常,包括1p,2q和6q的增益和1q,6p和8q的丢失。在这些新基因座中,1q,6q和8q与DLBCL患者的临床结局显着相关(p结论我们开发了一种新的计算方法vCGH,可根据淋巴瘤中GEP数据预测全基因组遗传异常。应用于其他类型的肿瘤,并可能显着增强癌症研究中功能重要的遗传异常的检测。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号